While genome-sequencing aficionados (what few there may be) focused attention on Roche's (OTC: RHHBY) bid for, and subsequent rejection by, Illumina
Break it down
Longtime Life Tech followers should be well aware of the company's consistency, but it's worth noting again, especially in light of the company's solid fourth quarter:
Sources: Morningstar and Life Technologies earnings release.
Life Tech calculated its revenue rather conservatively, with non-GAAP earnings clocking in $40 million below GAAP results. Even without that downward adjustment, Life Tech still set new revenue records, besting the $941 million earned in 2011's second quarter. Investors should take note of this consistency, because there is not an abundance of stable and profitable companies in this space to invest in. For reference, up-and-coming Pacific Biosciences of California
It might take a couple of quarters for that new low-cost machine to show up on earnings, but there are already signs that Life Tech is positioning itself for long-term sequencing success.
Let's take a look at some of the most important facts and figures from both Life Tech's earnings release and its subsequent conference call:
- 2011 free cash flow was $710 million on revenue of $3.7 billion.
- Non-GAAP organic revenue should grow by 2% to 4% in 2012, with the company issuing EPS guidance between $3.90 and $4.05.
- Life Tech revenue grew 2% in the Americas, 3% in Europe, and 9% in the Asia-Pacific region last year. Japanese revenue declined 3% on the year.
- E-commerce sales grew 12% in 2011. Over half the company's transactions are now processed through this platform.
- CEO Greg Lucier compared Life Tech's e-commerce platform to Amazon.com, noting that his company can ship bio-active products anywhere in the world within five days.
- Life Tech now has 900 employees in the Chinese region (including Taiwan and Hong Kong) and plans to add another 250 this year.
- Despite having $2.3 billion in long-term debt, Life Tech remains committed to a $300 million share repurchase, which comes on top of $100 million already spent on repurchases in just the past six months.
- Life Tech has $882 million in the bank -- plenty to meet this goal.
- Government and academic customers will be "challenged, but stable."
- The Ion Torrent sequencing platform should "grow significantly."
Foolish final thoughts
I remain quite excited about the breakneck drop in sequencing costs and its potential for broad adoption. The Ion Torrent segment only generated $278 million in fourth-quarter revenue, about a quarter of Life Tech's total. As plummeting costs make sequencing a common practice, that segment could very well become Life Tech's golden goose. It's certainly worth keeping your eye on.
Add Life Technologies to your Watchlist for all the genomic news you can shake a double helix at. Interested in a different stock that's having a similarly revolutionary impact on the medical industry? You've got to take a look at this brand-new free report, which explains what this company does and why it's such an incredible opportunity for smart investors. Find out everything you need to know about this rule-breaking multibagger -- click here to claim your free report now.